ITH Panoramica delle azioni Nektar Therapeutics, azienda biofarmaceutica, si concentra sulla scoperta e sullo sviluppo di terapie che modulano selettivamente il sistema immunitario per il trattamento di patologie autoimmuni. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Nektar Therapeutics Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Nektar Therapeutics Prezzi storici delle azioni Prezzo attuale dell'azione US$1.05 Massimo di 52 settimane US$1.69 Minimo di 52 settimane US$0.44 Beta 0.59 Variazione di 1 mese 6.49% Variazione a 3 mesi -9.40% Variazione di 1 anno 117.35% Variazione a 3 anni -89.93% Variazione a 5 anni -94.82% Variazione dall'IPO -90.57%
Notizie e aggiornamenti recenti
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08 Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.24 loss in 3Q 2023) Nov 09
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06
Vedi altri aggiornamenti
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08 Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.24 loss in 3Q 2023) Nov 09
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 05
New major risk - Revenue and earnings growth Nov 04
Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases Oct 29
Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia Oct 17
Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.27 loss in 2Q 2023) Aug 09
Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.72 loss in 1Q 2023) May 13
Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024 May 03
Nektar Therapeutics, Annual General Meeting, Jun 05, 2024 Apr 28 Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC Mar 20
Full year 2023 earnings released: US$1.45 loss per share (vs US$1.97 loss in FY 2022) Mar 06
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Mar 05 Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC Mar 04
Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 29
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 28
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2022) Nov 09
Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy Oct 14
New minor risk - Market cap size Oct 10
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer Sep 28
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis Sep 14
Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.85 loss in 2Q 2022) Aug 09
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Aug 08
Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
New minor risk - Market cap size Jul 25
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index Jun 25
New minor risk - Market cap size Jun 23
Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule Jun 03
First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.49 loss in 1Q 2022) May 10
Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023 May 10
Full year 2022 earnings released: US$1.97 loss per share (vs US$2.86 loss in FY 2021) Mar 01
CEO, President & Director recently sold €55k worth of stock Feb 23
Insufficient new directors Jan 01
CEO, President & Director recently sold €130k worth of stock Nov 20
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy Nov 10
Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 3Q 2021) Nov 05
Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress Sep 07
CEO, President & Director recently sold €64k worth of stock Aug 20
Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma Aug 17
Second quarter 2022 earnings released: US$0.85 loss per share (vs US$0.69 loss in 2Q 2021) Aug 05
Nektar Therapeutics Provides Earnings Guidance for the Year 2022 Aug 05
Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022 Jul 28 Nektar Promotes Jillian B. Thomsen to Senior Vice President
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index Jun 26
Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study May 24
CEO, President & Director recently sold €139k worth of stock May 20
First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.68 loss in 1Q 2021) May 07
Nektar Therapeutics, Annual General Meeting, Jun 08, 2022 May 02
John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nektar Therapeutics Apr 26
Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Development Program for Bempegaldesleukin (Bempeg) in Combination with Opdivo (Nivolumab) Apr 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022 Mar 02
Chief Research & Development Officer recently sold €105k worth of stock Feb 19
Nektar Therapeutics to Report Q4, 2021 Results on Feb 28, 2022 Feb 18
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, At the 63Rd American Society of Hematology (ASH) Annual Meeting Dec 14
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting Dec 01
Senior VP recently sold €245k worth of stock Nov 19
Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.61 loss in 3Q 2020) Nov 06
Insider recently sold €56k worth of stock Sep 26
Redhill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP and Nektar Therapeutics Enters into A Settlement and License Agreement with Aurobindo Pharma USA, Inc Sep 24
Insider recently sold €157k worth of stock Aug 19
Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.45 loss in 2Q 2020) Aug 08
RedHill Biopharma Inc., Astrazeneca AB and Astrazeneca Pharmaceuticals LP and Nektar Therapeutics Enters into Settlement and License Agreement with Apotex, Inc. and Apotex Corp. Resolving Their Patent Litigation in the U.S Jul 24
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity May 21
Chief Research & Development Officer recently sold €469k worth of stock May 20
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) May 19
Nektar Therapeutics Provides Revenue Guidance for the Full Year of 2021 May 08
First quarter 2021 earnings released: US$0.68 loss per share (vs US$0.78 loss in 1Q 2020) May 08
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals Mar 26
Full year 2020 earnings released: US$2.49 loss per share (vs US$2.52 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Biolojic Design, Ltd. Enters A Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against A Novel Target for the Potential Treatment of Autoimmune Disease Feb 26
Nektar Therapeutics to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Chief Research & Development Officer recently sold €446k worth of stock Feb 19
New 90-day high: €20.75 Feb 19
Nektar Therapeutics Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA in Patients with Squamous Cell Carcinoma of the Head and Neck Feb 18 Rendimenti per gli azionisti ITH DE Pharmaceuticals DE Mercato 7D 14.1% 1.2% 1.2% 1Y 117.3% -14.1% 10.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: ITH ha superato il German Pharmaceuticals che ha restituito -14.1 % nell'ultimo anno.
Rendimento vs Mercato: ITH ha superato il mercato German che ha restituito 10.1 % nell'ultimo anno.
Volatilità dei prezzi Is ITH's price volatile compared to industry and market? ITH volatility ITH Average Weekly Movement 10.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ITH è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 10% ) di ITH è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1990 137 Howard Robin www.nektar.com
Nektar Therapeutics, azienda biofarmaceutica, si concentra sulla scoperta e sullo sviluppo di terapie che modulano selettivamente il sistema immunitario per il trattamento di disturbi autoimmuni. Sviluppa NKTR-358, uno stimolatore di cellule T (Treg) regolatorie progettato per affrontare lo squilibrio del sistema immunitario alla base dei disturbi autoimmuni e delle condizioni infiammatorie croniche; PEG-CSF1, una proteina del fattore stimolante le colonie ematopoietiche modificata con polietilenglicole (PEG), progettata per modulare in modo selettivo i processi di risoluzione dell'infiammazione e che trova applicazione in diverse indicazioni terapeutiche, tra cui l'infiammazione acuta e cronica; l'asset agonista del recettore del fattore di necrosi tumorale (TNF) di tipo II (TNFR2), una molecola anticorpale bivalente utilizzata per stimolare selettivamente l'attività del recettore TNFR2, senza modulare la segnalazione del TNFR1; e NKTR-255, un agonista del recettore IL-15 progettato per potenziare la capacità naturale del sistema immunitario di combattere il cancro. L'azienda serve i suoi clienti negli Stati Uniti e a livello internazionale.
Mostra di più Nektar Therapeutics Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Nektar Therapeutics con la sua capitalizzazione di mercato? ITH statistiche fondamentali Capitalizzazione di mercato €205.26m Guadagni(TTM ) -€164.28m Ricavi(TTM ) €90.91m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) ITH Conto economico (TTM ) Ricavi US$93.14m Costo del fatturato US$29.99m Profitto lordo US$63.15m Altre spese US$231.45m Guadagni -US$168.30m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.91 Margine lordo 67.80% Margine di profitto netto -180.70% Rapporto debito/patrimonio netto 200.1%
Come si è comportato ITH nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/10 03:05 Prezzo dell'azione a fine giornata 2025/01/10 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Nektar Therapeutics è coperta da 34 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Richard Silver Barclays Aydin Huseynov Benchmark Company George Farmer BMO Capital Markets Equity Research
Mostra 31 altri analisti 
